Stockscreener 앱 받기
0.99
12.39%
-0.14
전일 마감가:
$1.13
열려 있는:
$1.08
하루 거래량:
829.19K
Relative Volume:
4.74
시가총액:
$4.40M
수익:
$72,100
순이익/손실:
$-3.60M
주가수익비율:
-0.5893
EPS:
-1.68
순현금흐름:
$-3.37M
1주 성능:
-25.00%
1개월 성능:
-18.18%
6개월 성능:
-50.75%
1년 성능:
-37.58%
1일 변동 폭
$0.98
$1.10
1주일 범위
$0.98
$1.34
52주 변동 폭
$0.841
$4.50
Silo Pharma Inc Stock (SILO) Company Profile
명칭
Silo Pharma Inc
전화
(718) 400-9031
주소
677 N. WASHINGTON BLVD, SARASOTA
SILO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SILO | 1.56 | 17.96M | 0 | 0 | 0 | 0.00 |
| GOODO | 22.16 | 372.90M | 0 | 0 | 0 | 0.00 |
| PSNYW | 0.141 | 297.56M | 2.07B | -1.42B | -1.37B | -0.1344 |
| MOBBW | 0.16 | 278.60M | 0 | 0 | 0 | 0.00 |
| SHMD | 2.61 | 114.98M | 0 | 0 | 0 | 0.00 |
| JUNE | 4.95 | 63.87M | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc 주식(SILO)의 최신 뉴스
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders - The Manila Times
Silo Pharma reports progress in PTSD treatment study - Investing.com
Silo Pharma Third Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023) - Yahoo Finance
SILOSilo Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant - GlobeNewswire
Silo Pharma, Inc. Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant - Marketscreener.com
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Orange Juice (OJX25) Quote - The Globe and Mail
Japan Ice Bank Silo Market By Application - Third Eye News
SILO Pharma (NASDAQ:SILO) Stock Quotes, Forecast and News Summary - Benzinga
Exclusive Come Home Trailer Previews Horror Thriller Movie Featuring Silo Stars - ComingSoon.net
Egypt: General Company for Silos’s profits rise 45.6% YoY in FY2023/24 - ZAWYA
Silvis Materials Awarded $1 Million NSF SBIR Phase II Grant to Reduce Emissions in Packaging and Building - EIN News
FDA Grants Accelerated Approval to Gilead’s Livdelzi for Primary Biliary Cholangitis - The Healthcare Technology Report.
Serpin Pharma and Uniklinikum Erlangen Team Up for a Clinical Trial to Prevent Acute Kidney Injury - EIN News
New Silo Season 2 Character Is Very Closely Copying An Iconic 2000s TV Show - Screen Rant
Roli Mosimann (Swans / Wiseblood / The The) has died - Brooklyn Vegan
SosMula Finally Delivers "SLEEZ RELIGION" - HotNewHipHop
Silo season 2: Apple TV Plus release date, likely cast, story rumors, and more news about the sci-fi show's return - TechRadar
Silo Pharma completes pre-IND meeting with FDA on SPC-15 for PTSD - BioWorld Online
Financial Metrics Exploration: Understanding SILO Pharma Inc (SILO) Through Ratios - The Dwinnex
SILO Pharma Inc [SILO] Insider Activity: An Update for Investors - Knox Daily
Silo Pharma moves forward with PTSD treatment SPC-15 - Investing.com
Silo Pharma moves forward with PTSD treatment SPC-15 By Investing.com - Investing.com Australia
SILO Pharma Inc Inc. (SILO) Price Performance: A Technical Analysis Perspective - The InvestChronicle
SILO’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Silo Pharma Outlines Strategic Direction and Innovative Pipeline - TipRanks
Silo Pharma Announces Completion of FDA Pre-IND Meeting to - GlobeNewswire
Psychedelic Drugs Market to Grow by USD 1.37 Billion from 2024-2028, Driven by Increasing Mental Health Disorders, Report Highlights AI's Impact on the Market LandscapeTechnavio - The Malaysian Reserve
Silo Pharma (NASDAQ:SILO) Shares Down 6% - Defense World
Adversity is less terrifying than hope: SILO Pharma Inc (SILO) - SETE News
SILO Pharma Inc (SILO)’s stock price range in the last year - US Post News
Metric Deep Dive: Understanding SILO Pharma Inc (SILO) Through its Ratios - The Dwinnex
SILO Pharma Inc [SILO] Investment Guide: What You Need to Know - Knox Daily
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million - Quantisnow
SILO’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Silo Pharma advances ketamine implant for chronic pain treatment - Investing.com India
Silo Pharma Shares Jump 11% on Ketamine-Treatment Partnership - MarketWatch
Silo Pharma advances ketamine implant for chronic pain treatment By Investing.com - Investing.com UK
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic - GlobeNewswire
SILO Pharma Inc’s latest rating changes from various analysts - Knox Daily
Silo Pharma partners with WuXi AppTec for MS peptide study - Investing.com India
Closing Figures: SILO Pharma Inc (SILO)’s Negative Finish at 1.18, Down -13.24 - The Dwinnex
Silo Pharma partners with WuXi AppTec for MS peptide study By Investing.com - Investing.com UK
SILO’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
How does SILO’s price to cash per share ratio compare in the market? - US Post News
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide - GlobeNewswire
Taking on analysts’ expectations and winning: SILO Pharma Inc (SILO) - SETE News
Examining SILO Pharma Inc (SILO) more closely is necessary - US Post News
Investing in SILO Pharma Inc (SILO): What You Must Know - Knox Daily
SILO’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Silo Pharma Inc (SILO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):